Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Study results from Duke University broaden understanding of cancer vaccines
June 10th, 2009
According to recent research published in the journal Clinical Cancer Research, "Wilms tumor protein (WT1) is overexpressed in most leukemias and many solid tumors and is a promising target for tumor immunotherapy. WT1 peptide-based cancer vaccines have been reported but have limited application due to HLA restriction of the peptides." "We sought to vaccinate using adenoviral (Ad) vectors encoding tumor-associated antigens such as WT1 that can stimulate tumor-associated antigen-specific immunity across a broad array of HLA types and multiple class I and class II epitopes. We developed a novel Ad vector encoding a truncated version of WT1 (Ad-tWT1) lacking the...
Source: Vaccine Weekly (2009-06-10)
|
